The Claim
Among patients with coronary artery disease and lipid-rich plaques defined by maxLCBI4mm ≥324.7, an on-treatment LDL-C level below 55 mg/dL is associated with a 77% lower risk of major adverse cardiac events over a median follow-up of 1109 days.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In patients with coronary artery disease and high-risk lipid-rich plaques, maintaining LDL cholesterol below 55 mg/dL while on treatment is associated with a 77% reduction in the occurrence of major cardiac events over approximately three years.
See the scientific wording
Among patients with coronary artery disease and lipid-rich plaques defined by maxLCBI4mm ≥324.7, achieving an on-treatment LDL-C level below 55 mg/dL is associated with a 77% lower risk of major adverse cardiac events (adjusted HR = 0.23, 95% CI: 0.09–0.57) over a median follow-up of 1109 days, suggesting that intensive lipid-lowering may be particularly beneficial for this plaque phenotype.
When LDL cholesterol drops below 55 mg/dL, less cholesterol enters the artery walls, and existing cholesterol is pulled out of fatty plaques. This reduces swelling and immune cell buildup inside the plaques, making their outer walls thicker and stronger. As a result, the plaques no longer break open and trigger blood clots that cause heart attacks.
What the research says
1 studyIn people with fatty, unstable plaques in their heart arteries, getting LDL cholesterol below 55 mg/dL with medication greatly lowers their risk of heart attacks or needing more procedures — but only if they have these specific dangerous plaques.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.